Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Rhea-AI Summary

Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis conditions, has announced its upcoming presentation at The Citizens Life Sciences Conference 2025.

Brian Windsor, Ph.D., who serves as President and Chief Executive Officer, will deliver the presentation on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.

Interested parties can access the presentation through a live webcast at the company's investor relations website. The recording will remain available for 90 days after the event.

Positive

• Company is developing first-in-class medicines for orphan pulmonary and fibrosis indications, targeting potentially lucrative niche markets

Negative

• None.

AUSTIN, Texas, April 30, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at The Citizens Life Sciences Conference 2025 on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.

A live webcast of the event can be accessed at https://ir.reintx.com/events-presentations. A replay of the webcast will be available for 90 days following the presentation.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. For more information, please visit the company's website at reintx.com, or follow them on LinkedIn and X.

Rein Investor Relations & Media Contact:
Argot Partners
rein@argotpartners.com
212-600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/rein-therapeutics-to-present-at-the-citizens-life-sciences-conference-2025-302443270.html

SOURCE Rein Therapeutics, Inc.

FAQ

When is Rein Therapeutics (RNTX) presenting at The Citizens Life Sciences Conference 2025?

Rein Therapeutics (RNTX) will present on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.

How can I watch Rein Therapeutics' (RNTX) presentation at The Citizens Life Sciences Conference?

You can watch the live webcast at https://ir.reintx.com/events-presentations. A replay will be available for 90 days after the presentation.

What type of medicines is Rein Therapeutics (RNTX) developing?

Rein Therapeutics is developing first-in-class medicines focused on orphan pulmonary and fibrosis indications to address unmet medical needs.

Who will represent Rein Therapeutics (RNTX) at The Citizens Life Sciences Conference 2025?

Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics, will present at the conference.

Where is The Citizens Life Sciences Conference 2025 with Rein Therapeutics (RNTX) being held?

The conference is being held in New York, NY.